GLP-1 drugs such as Wegovy, Ozempic, and Zepbound are a class of medications primarily taken to treat Type 2 diabetes and, more recently, obesity. Research indicates many people taking GLP-1s for ...
Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than a third have stopped ...
Nearly 60% of Americans who started taking weight-loss drugs between 2014 and 2023 didn’t continue long enough to see meaningful health benefits, according to a study of people covered by ...
Blue Cross Blue Shield of Michigan will drop coverage GLP-1 obesity drugs in fully insured large group commercial plans ...
We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Here’s our process. Injectable GLP-1 medication can help manage ...
The number of American teens and young adults who've been prescribed one of the new GLP-1 weight-loss drugs soared nearly seven-fold between 2020 and 2023, a new report finds. That's compared to ...
Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than a third have stopped, new ...